For many women who struggle with the many ramifications of metabolic syndromes that come with being woman, and the lack of consensus information on how to manage the many complaints we have, the news this week that the acronym PCOS (Polycystic Ovary Syndrome) has been transitioned to a more evidence based name, more akin to the symptoms the many sufferers present with, is very welcome.

PCOS remains the official clinical designation used by the American College of Obstetricians and Gynecologists (ACOG) and the ICD-10 coding system, but we can all begin the mental shift towards making progress on the many parts of PMOS( Polyendocrine Metabolic Ovarian Syndrome).

As Physicians/Clinicians, it is essential to view this shift not merely as a semantic update, but as a critical realignment of the syndrome’s pathophysiology with its clinical presentation.

PCOS had its limitations and failure in modern reproductive endocrinology in two major areas:

1. The "Cyst" Fallacy: The "cysts" described in the Rotterdam criteria are actually antral follicles, arrested in development, not true adnexal cysts.

2. Organ-Specific Bias: The name "PCOS" suggests a primary ovarian disease, whereas a multitude of research confirms that it is a multisystem endocrine and metabolic disorder characterized by insulin resistance and androgen excess.

The proposed new name PMOS(Polyendocrine Metabolic Ovarian Syndrome) aims to center the metabolic drivers that dictate long-term morbidity highlighting data from ACOG and multiple endocrine societies that show:

● Insulin Resistance: up to 70% of patients with PMOS exhibit insulin resistance regardless of BMI.

● Cardiometabolic Risk: Patients with PMOS face a significantly higher risk of Type 2 Diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular events.

● Research Parity: Renaming the condition helps decouple it from "fertility only" and encourages funding in metabolic health, long-term vascular biology, genetics and vitality optimization.

Additionally, based on the shift, guidelines will then emphasize a "Life Course" approach in catering to the needs of presenting patients by 1) Prioritizing early and frequent screening for glucose intolerance and lipid profiles, 2) Validating the use of insulin sensitizers (e.g., Metformin, Inositol) alongside or in lieu of combined oral contraceptives (COCs) in active management and 3) Reducing the psychological distress for patients of "having cysts" and helps them focus on metabolic and lifestyle interventions that provide the highest therapeutic yield.

Furthermore, the hope for the future of PMOS research lies in phenotyping, where we move away from a "one-size-fits-all" diagnosis toward identifying specific clusters—such as the hyperandrogenic-metabolic phenotype versus the ovulatory-metabolic phenotype- this would go a long way in guiding treatment architecting for the individual patient.

Although there is still so much work to be done, a name change is the first step in dismantling the diagnostic silos, ensuring that whether a patient is in the OB/GYN office or the Primary Care clinic, the metabolic gravity of the condition is recognized and treated with the appropriate clinical rigor.

Be Reclaimed & Well,

@DrSelakobs

#SeleipiriAkobo#BurnoutArchitect#MetabolicHealth#ReproductiveEndocrinology#HealthEquity#ReclaimMedicalNWellness